As an interesting aside to this – I read an article abstract recently where contrary to “response driven” management of treatment in the past – the author was raising the question whether – future treatment might become guided by assessing “resistance”.

I relapsed after Boceprevir + Ribavirin + interferon a couple of years ago. I am G1. My problem was white & red blood cells dropping dangerously low resulted in lowering of dose. I’ve been worried about what resistance might have developed ever since, so I’ll be closely following this topic. Here’s something I just found that’s rather hopeful:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961994/ This study includes the following paragraph [Note DCV = Daclatasvir]:

“A combination of DCV and a nucleotide analogue inhibitor of HCV RNA-dependent RNA polymerase, sofosbuvir, with or without ribavirin for 24 wk achieved SVR in 100% of untreated HCV genotype 1a and 1b patients (n = 44) as well as in HCV genotype 1a and 1b patients (n = 41) who failed to respond to prior treatment with telaprevir or boceprevir, peginterferon and ribavirin. SVR was achieved in 93% of patients infected with HCV genotypes 2 and 3 (n = 44)[89,90].”

41 patients who failed telaprevir and boceprevir must surely have included people with resistant varieties. Interesting that the excellent result was achieved both with and without Ribavirin.